Recombinant Anti-FGF9/GAF antibody [EPR19937] (ab206408)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19937] to FGF9/GAF
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-FGF9/GAF antibody [EPR19937]
See all FGF9/GAF primary antibodies -
Description
Rabbit monoclonal [EPR19937] to FGF9/GAF -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human FGF9/GAF active protein; human fetal brain, fetal kidney and ovary cancer lysates; mouse kidney and brain lysates; rat brain lysate; C6, PC-12, NIH/3T3 and U-87 MG whole cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR19937 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab206408 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Detects a band of approximately 26 kDa (predicted molecular weight: 23 kDa).
|
Notes |
---|
WB
1/1000. Detects a band of approximately 26 kDa (predicted molecular weight: 23 kDa). |
Target
-
Function
May have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors. -
Tissue specificity
Glial cells. -
Involvement in disease
Defects in FGF9 are the cause of multiple synostoses syndrome type 3 (SYNS3) [MIM:612961]. Multiple synostoses syndrome is an autosomal dominant condition characterized by progressive joint fusions of the fingers, wrists, ankles and cervical spine, characteristic facies and progressive conductive deafness. -
Sequence similarities
Belongs to the heparin-binding growth factors family. -
Post-translational
modificationsThree molecular species were found (30 kDa, 29 kDa and 25 kDa), cleaved at Leu-4, Val-13 and Ser-34 respectively. The smaller ones might be products of proteolytic digestion. Furthermore, there may be a functional signal sequence in the 30 kDa species which is uncleavable in the secretion step.
N-glycosylated. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 2254 Human
- Entrez Gene: 14180 Mouse
- Entrez Gene: 25444 Rat
- Omim: 600921 Human
- SwissProt: P31371 Human
- SwissProt: P54130 Mouse
- SwissProt: P36364 Rat
- Unigene: 111 Human
see all -
Alternative names
- FGF 9 antibody
- FGF-9 antibody
- FGF9 antibody
see all
Images
-
All lanes : Anti-FGF9/GAF antibody [EPR19937] (ab206408) at 1/1000 dilution
Lane 1 : Human FGF9/GAF active protein
Lane 2 : Human FGF16 recombinant protein
Lane 3 : Human FGF20 recombinant protein
Lysates/proteins at 0.01 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 23 kDa
Observed band size: 23 kDaBlocking/Dilution buffer: 5% NFDM/TBST.
Exposure times: Lane 1/2: 1 seconds; Lane 3: 15 seconds.
Human FGF9/GAF active protein contains aa1-208; FGF16 and FGF20 recombinant protein contain aa1-203 and aa4-208 respectively, both with His-Tag®.
-
All lanes : Anti-FGF9/GAF antibody [EPR19937] (ab206408) at 1/1000 dilution
Lane 1 : Human fetal brain lysate
Lane 2 : Human fetal kidney lysate
Lane 3 : Human ovary cancer lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/100000 dilution
Predicted band size: 23 kDa
Observed band size: 26 kDa why is the actual band size different from the predicted?Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure times: Lane 1/2: 15 seconds; Lane 3: 30 seconds.
The MW observed is consistent with the literature (PMID:16452189, PMID: 25925261).
-
All lanes : Anti-FGF9/GAF antibody [EPR19937] (ab206408) at 1/1000 dilution
Lane 1 : Mouse kidney lysate
Lane 2 : Mouse brain lysate
Lane 3 : Rat brain lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 23 kDa
Observed band size: 26 kDa why is the actual band size different from the predicted?Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure times: Lane 1/2: 15 seconds; Lane 3: 30 seconds.
The MW observed is consistent with the literature (PMID:16452189, PMID: 25925261).
-
All lanes : Anti-FGF9/GAF antibody [EPR19937] (ab206408) at 1/1000 dilution
Lane 1 : C6 (Rat glial tumor cell line) whole cell lysate
Lane 2 : PC-12 (Rat adrenal gland pheochromocytoma cell line) whole cell lysate
Lane 3 : NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate
Lane 4 : U-87 MG (Human glioblastoma-astrocytoma epithelial cell line) whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 23 kDa
Observed band size: 26 kDa why is the actual band size different from the predicted?Blocking/Dilution buffer: 5% NFDM/TBST.
Exposure times: Lane 1-3: 15 seconds; Lane 4: 3 minutes.
The MW observed is consistent with the literature (PMID:16452189, PMID: 25925261).
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (6)
ab206408 has been referenced in 6 publications.
- Zhao F et al. FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism. Front Pharmacol 13:850128 (2022). PubMed: 35517790
- Yuan J et al. LncRNA NEAT1 promotes proliferation of ovarian cancer cells and angiogenesis of co-incubated human umbilical vein endothelial cells by regulating FGF9 through sponging miR-365: An experimental study. Medicine (Baltimore) 100:e23423 (2021). PubMed: 33545926
- Fan X et al. Human endometrium-derived stem cell improves cardiac function after myocardial ischemic injury by enhancing angiogenesis and myocardial metabolism. Stem Cell Res Ther 12:344 (2021). PubMed: 34112245
- Wei W et al. miR‑486‑5p suppresses gastric cancer cell growth and migration through downregulation of fibroblast growth factor 9. Mol Med Rep 24:N/A (2021). PubMed: 34490480
- Xiao X et al. Oxymatrine inhibits proliferation and apoptosis of human breast cancer cells through the regulation of miRNA-140-5P. Am J Transl Res 13:13674-13682 (2021). PubMed: 35035706
- Asakawa M et al. Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis. Sci Rep 9:19601 (2019). PubMed: 31862949